AnalystsSerge BelangerSerge Belanger's Stock Forecasts
AnalystsSerge Belanger
Analyst Ranking
Top 2%
#71 out of 5515 analysts
Average Return
+19.06%
Win Rate
53%231 out of 440
Risk vs Reward
Poor
Good
Serge Belanger's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Trevi Therapeutics IncTRVI | +426.92% | $2.60 | $13.70 | 2024-12-04 - 2025-12-03 | Buy |
Liquidia CorpLQDA | +337.57% | $14.18 | $62.03 | 2025-05-28 - 2026-05-27 | Buy |
Arcutis Biotherapeutics IncARQT | +297.44% | $2.34 | $9.30 | 2023-11-06 - 2024-11-05 | Buy |
Arcutis Biotherapeutics IncARQT | +297.44% | $2.34 | $9.30 | 2023-11-06 - 2024-11-05 | Buy |
Trevi Therapeutics IncTRVI | +278.35% | $2.91 | $11.01 | 2024-11-08 - 2025-11-07 | Buy |
Serge Belanger Analyst Color
Get additional color on Serge Belanger's coverage of popular stocks
Serge Belanger's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Xenon Pharmaceuticals IncXENE | 17 | Buy | $60.00 | +50.94% | Maintains | a day ago |
Biocryst Pharmaceuticals IncBCRX | 20 | Buy | $16.00 | +84.33% | Reiterates | 11 days ago |
Evommune IncEVMN | 1 | Buy | $28.00 | +190.16% | Initiates Coverage On | 25 days ago |
Liquidia CorpLQDA | 37 | Buy | $110.00 | +64.47% | Maintains | a month ago |
Cytokinetics IncCYTK | 30 | Buy | $112.00 | +62.84% | Maintains | a month ago |
Collegium Pharmaceutical IncCOLL | 29 | Buy | $46.00 | +102.02% | Maintains | a month ago |
Arcutis Biotherapeutics IncARQT | 27 | Buy | $40.00 | +57.60% | Maintains | a month ago |
Pacira Biosciences IncPCRX | 30 | Buy | $33.00 | +33.66% | Maintains | a month ago |
Veradermics IncMANE | 2 | Buy | $164.00 | +53.63% | Maintains | 2 months ago |
Viridian Therapeutics IncVRDN | 24 | Buy | $34.00 | +54.55% | Maintains | 3 months ago |
Heron Therapeutics IncHRTX | 22 | Hold | N/A | N/A | Downgrades | 4 months ago |
Oculis Holding AgOCS | 5 | Buy | $38.00 | +274.75% | Maintains | 4 months ago |
Trevi Therapeutics IncTRVI | 23 | Buy | $23.00 | +53.85% | Reiterates | 4 months ago |
Moonlake ImmunotherapeuticsMLTX | 16 | Buy | $30.00 | +142.13% | Maintains | 4 months ago |
Amphastar Pharmaceuticals IncAMPH | 10 | Hold | N/A | N/A | Downgrades | 4 months ago |
Ocular Therapeutix IncOCUL | 8 | Buy | $18.00 | +80.18% | Reiterates | 4 months ago |
Esperion Therapeutics IncESPR | 22 | Hold | N/A | N/A | Downgrades | 5 months ago |
Kalvista Pharmaceuticals IncKALV | 24 | Hold | N/A | N/A | Downgrades | 5 months ago |
Cormedix IncCRMD | 22 | Buy | $15.00 | +94.30% | Maintains | 5 months ago |
Newamsterdam Pharma Co NvNAMS | 11 | Buy | $48.00 | +113.43% | Maintains | 7 months ago |
Evolus IncEOLS | 17 | Hold | N/A | N/A | Reiterates | 9 months ago |
Omeros CorpOMER | 9 | Hold | N/A | N/A | Reiterates | a year ago |
Clearside Biomedical IncCLSDQ | 16 | Hold | $45.00 | N/A | Downgrades | a year ago |
Verrica Pharmaceuticals IncVRCA | 19 | Hold | N/A | N/A | Reiterates | a year ago |
Revance Therapeutics IncRVNC | 20 | Hold | N/A | N/A | Reiterates | 2 years ago |
Dice Therapeutics IncDICE2 | 2 | Hold | N/A | N/A | Downgrades | 3 years ago |
Tricida IncTCDAQ | 2 | Hold | N/A | N/A | Downgrades | 4 years ago |
Phasebio Pharmaceuticals IncPHASQ | 3 | Hold | N/A | N/A | Downgrades | 4 years ago |
Aerie Pharmaceuticals IncAERI | 5 | Hold | N/A | N/A | Downgrades | 4 years ago |
Clarus Therapeutics Holdings IncCRXTQ | 4 | Hold | N/A | N/A | Downgrades | 4 years ago |
Akebia Therapeutics IncAKBA | 1 | Hold | N/A | N/A | Downgrades | 4 years ago |
Zogenix IncZGNX | 3 | Hold | N/A | N/A | Downgrades | 5 years ago |
Flexion Therapeutics IncFLXN1 | 1 | Buy | $18.00 | N/A | Maintains | 5 years ago |
Calcimedica IncCALC | 2 | Hold | N/A | N/A | Downgrades | 5 years ago |
Gw Pharmaceuticals PLCGWPH | 3 | Hold | N/A | N/A | Downgrades | 6 years ago |
Zynerba Pharmaceuticals IncZYNE | 1 | Hold | N/A | N/A | Downgrades | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.